Viracta Therapeutics Q2 FY22: net loss $10.6M; diluted EPS $0.28

Key figures from this report

These are the numbers Viracta Therapeutics reported for Q2 FY22, the quarter ended Jun 30, 2022, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Net income−$10.6MNo year-earlier figure tagged10-Q income statement, on EDGAR
2. Diluted EPS$0.28No year-earlier figure tagged10-Q income statement, on EDGAR
3. Cash and cash equivalents$81.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
4. Cash from operations−$9.0MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters